Form 4: BeyondSpring Inc. Director Matthew Kirkby Granted Stock Options

Director Matthew Kirkby of BeyondSpring Inc. receives stock options to purchase 25,763 ordinary shares.

Summary

• On April 21, 2025, Matthew Kirkby, a director of BeyondSpring Inc., was granted stock options to purchase 25,763 ordinary shares of the company.
• The exercise price of these options is $1.31 per share.
• The options vest on April 21, 2026, contingent upon Kirkby's continued service with BeyondSpring Inc.
• The options expire on April 21, 2035.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is relatively standard.
• The number of options granted would need to be compared to similar companies of BeyondSpring's size and stage to determine if it is in line with industry norms.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to increase shareholder value.

Key Dates

Keywords

stock options, director, BYSI, BeyondSpring Inc., Matthew Kirkby, equity compensation, Form 4